PANews 3月21日消息，YZi Labs在X平台发文宣布Jane He担任其普通合伙人，领导生物科技投资，同时为公司在AI和Web3领域的广泛战略贡献力量。Jane的任命正值YZi Labs在近期品牌重塑后，将其投资重点从Web3扩展至AI和生物科技领域。
据介绍，在加入YZi Labs之前，Jane曾担任一家香港对冲基金的投资者和首席运营官，专注于生物科技和创新驱动领域的增长型投资。她的投资组合和研究涵盖癌症治疗（免疫疗法、细胞疗法、抗体药物偶联物）、代谢治疗（用于肥胖和2型糖尿病的GLP-1药物）、寡核苷酸疗法（mRNA、siRNA、ASO）、基因编辑、测序和医疗设备。她还积极探索AI与生物科技交叉领域的机会。Jane曾在另类投资管理公司PAAMCO Prisma担任领导职务，负责管理其在亚洲其他基金的投资。Jane拥有斯坦福大学MBA学位，并以Arjay Miller学者身份毕业。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.